Funny, how with the TEVA recommedation you cited, that they gave thought to the hypothetical of lovenox being approved mid-2011 but no concern at all to copaxone generic being approved at all, which would be a calamity for TEVA share price.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.